Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

hieved a partial response with a median response duration of 9 months.  An additional 6 patients receiving the combination (40%) achieved stable disease.  The combination was well tolerated with no unexpected safety events.

The investigators concluded that perifosine in combination with sorafenib has significant anti-lymphoma activity in relapsed/refractory HL, and that perifosine as a single agent induced prolonged responses in high-risk, heavily pretreated CLL patients.

Abstract # 1842:  "Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)"Study Background:  In this Phase 2 study, 12 patients with advanced CLL began treatment with single agent perifosine at 50 mg BID. Patients on study were heavily pre-treated having had a median of 4 prior lines of therapy with 75% of patients classified as Rai stage IV.

Results:  1 patient achieved a partial response (5 months on treatment) and 5 additional patients achieved stable disease (median duration of 4.25 months), for an overall 50% clinical benefit rate (PR + SD).  Perifosine was well tolerated with minimal dose modifications.

Abstract #3064: "Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)"Additionally, the final dataset from the Phase 1 study of perifosine + lenalidomide (Revlimid®) + dexamethasone was also presented during the ASH meeting.  The final data showed a 73% objective response rate (minimal response or better) with a 50% PR or better, a median Progression-Free Survival of 10.8 months, and a median duration for Overall Survival of 30.6 months.  The myeloma investigators concluded that perifosine in combination with lenalidomide + dexamethasone was well tolerated even at the highest doses used, and demonstrated encouraging clini
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, ... to its investment in development and manufacturing capabilities with ... Karl Mueller , Particle Sciences, Associate Director Clinical ... pace adding clean room square footage, equipment and staff ... clients.  The company now has over 6000ft 2 ...
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation (ODEV) ... Stem, the latest addition to its growing hip ... intended for use in total hip arthroplasty and ... Alpine was developed based ... ODEV,s engineers worked closely with a select team ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... regarding WellPoint Inc. (NYSE: WLP ), Tekmira ... (NYSE: ZTS ), Sanofi SA (NYSE: ... wealth members receive these notes ahead of publication. To ... http://www.analystsreview.com/6142-100free . , ,-- ,WellPoint Inc. Research Reports ,WellPoint ...
Breaking Medicine Technology:Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The use ... blood thinners is growing at a rapid pace, even ... mount in courts around the U.S., Bernstein Liebhard LLP ... Journal of Medicine, within a year of its 2011 ... Xarelto as warfarin, a blood thinner that has been ...
(Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
(Date:9/2/2014)... a large population-based study of randomly selected participants ... (MCI) occurred twice more often in individuals diagnosed ... association was only observed in middle-aged participants (50-65 ... association vanished. This study is published in the ... concept of MCI describes an intermediate state between ...
(Date:9/2/2014)... Medex Analytic Services is delighted ... in Coral Springs, Fla. due to their greater than ... objectives for the 2014 year by distinguishing Medex in ... requested a higher level of service and professionalism in ... and the industry has responded.” , The location of ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... known that diabetes, one of the world’s leading debilitating diseases, ... 194 million adults worldwide. Therefore, there is a huge demand ... the patients. ,There are two types of diabetes: ... for approximately 5% of all the cases. This type is ...
... been used by a pediatric research team to scrutinize ... small defects that lead to genetic diseases //. ... detect these abnormalities, the new research may lead to ... that lead to mental retardation. ,“For years, ...
... in Australia have been linked to the work place each ... //and the University of Sydney has shown that about 1,600 ... asbestos, passive smoking, fumes and exhaust at work. Several cases ... a work related origin. ,Professor Lin Fritschi, lead ...
... are planning to demand the government to levy heavy tax ... mainly combat the nation's obesity epidemic. The issue mainly addresses ... of salt added to burgers and processed foods. The ... to obesity. Due to this the sales of soft drinks ...
... CHICAGO - Abnormal glucose metabolism, which occurs when the ... twice as common among patients //with chronic nerve dysfunction ... may be a risk factor for the condition, according ... in the August 2006 print issue of Archives of ...
... have left its impact on the six million care givers in ... because of caring //. ,The survey revealed that only ... GP while 90% of them considered that they should be offered ... that their own health problems affected their ability to care. Besides ...
Cached Medicine News:Health News:Inhaled Insulin: A New Modality for Management of Diabetes 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 3Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 4Health News:Work Related Cancer on the Rise in Australia 2Health News:Abnormal Glucose Metabolism May Contribute to Chronic Nerve Disorder 2Health News:Care Workers Need Some Care Too 2
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: